Evidence map›Paper›PMID 42062571›Full record

ArticleExperimental & molecular medicine2026

First-in-human and multicenter phase I study of OSCA therapy for knee osteoarthritis.

Dae Keun Suh, Sang Hak Lee, Yohan Bae, Hee-Jin Kang, Seunghee Lee, Mijin Kim, JongCheon Na, Ali Mobasheri, Kyung-Sun Kang, Kyoung Ho Yoon

Abstract readMulticenter StudyClinical Trial, Phase I
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dae Keun Suh *Department of Orthopaedic Surgery, Kyung Hee University Hospital 23, Seoul, Republic of Korea.
Sang Hak Lee *Department of Orthopaedic Surgery, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Yohan BaeKangstem Biotech Co., Ltd, Hongwoo Building, Seoul, Republic of Korea.
Hee-Jin KangKangstem Biotech Co., Ltd, Hongwoo Building, Seoul, Republic of Korea.
Seunghee LeeStem Cell and Regenerative Bioengineering Institute, Global R&D Center, Kangstem Biotech Co. Ltd, Seoul, Republic of Korea.
Mijin KimStem Cell and Regenerative Bioengineering Institute, Global R&D Center, Kangstem Biotech Co. Ltd, Seoul, Republic of Korea.
JongCheon NaKangstem Biotech Co., Ltd, Hongwoo Building, Seoul, Republic of Korea.
Ali MobasheriResearch Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0001-6261-1286
Kyung-Sun KangStem Cell and Regenerative Bioengineering Institute, Global R&D Center, Kangstem Biotech Co. Ltd, Seoul, Republic of Korea. kangpub@snu.ac.kr.ORCID http://orcid.org/0000-0002-9322-741X
Kyoung Ho YoonDepartment of Orthopaedic Surgery, Kyung Hee University Hospital 23, Seoul, Republic of Korea. kyoungho@khmc.or.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knee osteoarthritis is a degenerative joint disease, with no fundamental cure beyond pain relief and anti-inflammation. This phase I, multicenter, open-label, dose-escalation trial evaluated the safety, tolerability, and preliminary efficacy of OSCA, an intra-articular injection co-formulation of osiramestrocel (allogeneic mesenchymal stromal cells) and cartilage acellular matrix, in patients with Kellgren-Lawrence (K&L) grade 2 or 3 knee osteoarthritis. Twelve patients received a single intra-articular injection of OSCA at low (2.5 × 10

Indexed as

Mesenchymal Stem Cell TransplantationOsteoarthritis, KneeAgedFemaleHumansInjections, Intra-ArticularMagnetic Resonance ImagingMaleMiddle AgedTreatment Outcome

Identifiers

PMID42062571
PMCPMC13234111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.